Regeneration initiating cells

• US 7,527,968 B2
• Filed: 07/29/2003
• Issued: 05/05/2009
• Est. Priority Date: 07/29/2002
• Status: Expired due to Fees

• Current Assignee: Robarts Research Institute
• Original Assignee: Robarts Research Institute
• Inventors: Bhatia, Mickie
• Primary Examiner(s): Davis; Ruth A
• Application Number:
  US10/523,357
• Publication Number:
  US 20060140913A1
• Time in Patent Office: 2,107 Days
• Field of Search: 435/325, 435/366, 435/372
• US Class Current: 435/325
• CPC Class Codes: A61K 35/14 Blood; Artificial blood perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61P 5/48 of the pancreatic hormones

Abstract

Methods and compositions for treating hyperglycemia and pancreatic damage as well as stimulating the repair or regeneration of islet cells are disclosed.

Claims

1. A method of treating pancreatic damage comprising administering isolated regeneration initiating cells to an animal in need thereof, wherein the regeneration initiating cells have the surface marker c-kit and at least one of CD34 and AC133.

2. The method according to claim 1 wherein the regeneration initiating cells are derived from a source selected from the group consisting of bone marrow, peripheral blood, umbilical cord blood or placenta.

3. The method according to claim 2 wherein the regeneration initiating cell has at least one additional marker selected from the group consisting of KDR, Tie-1/2, Tek-1/2, VEGF-receptor families, CD31, and angiopoietin receptors.

4. The method according to claim 1 wherein the regeneration initiating cell is human.

5. The method according to claim 1 for the treatment of Diabetes.

6. The method according to claim 5 wherein the diabetes is non-insulin dependent Type II diabetes.

7. The method according to claim 1 wherein said animal is a human.

8. The method according to claim 1 wherein the cells are low density mononuclear lymphocytes.

9. The method according to claim 1 for the treatment of hyperglycemia.